Lakefront Biotherapeutics (GLPGF) Income from Discontinued Operations (2020 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Income from Discontinued Operations for 6 consecutive years, with $225498.2 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Discontinued Operations rose 115.94% year-over-year to $225498.2 in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 97.98% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 98.07% from the prior year.
• Income from Discontinued Operations was $225498.2 for Q2 2026 at Lakefront Biotherapeutics, down from $709471.9 in the prior quarter.
• Over five years, Income from Discontinued Operations peaked at $80.5 billion in Q4 2024 and troughed at -$19.2 million in Q3 2023.
• A 4-year average of $5.9 billion and a median of $1.7 million in 2023 frame the typical range for Income from Discontinued Operations.
• Across the five-year window, Income from Discontinued Operations soared 37713.17% in 2024 and tumbled 130.39% in 2025, its largest moves.
• Over 4 years, Income from Discontinued Operations stood at $212.8 million in 2023, then soared by 37713.17% to $80.5 billion in 2024, then plunged by 97.99% to $1.6 billion in 2025, then tumbled by 99.99% to $225498.2 in 2026.
• The last three Income from Discontinued Operations figures came in at $225498.2 (Q2 2026), $709471.9 (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.